Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
Total Valuation
Edwards Lifesciences has a market cap or net worth of $40.65B. The enterprise value is $40.50B.
Market Cap$40.65B
Enterprise Value$40.50B
Share Statistics
Edwards Lifesciences has 585,755,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding585,755,500
Owned by Insiders0.94%
Owned by Institutions1.37%
Financial Efficiency
Edwards Lifesciences’s return on equity (ROE) is 0.42 and return on invested capital (ROIC) is 10.72%.
Return on Equity (ROE)0.42
Return on Assets (ROA)0.32
Return on Invested Capital (ROIC)10.72%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee344.27K
Profits Per Employee263.91K
Employee Count15,800
Asset Turnover0.42
Inventory Turnover1.03
Valuation Ratios
The current PE Ratio of Edwards Lifesciences is 10.60. Edwards Lifesciences’s PEG ratio is 0.05.
PE Ratio10.60
PS Ratio7.62
PB Ratio4.43
Price to Fair Value4.43
Price to FCF152.63
Price to Operating Cash Flow81.59
PEG Ratio0.05
Income Statement
In the last 12 months, Edwards Lifesciences had revenue of 5.44B and earned 4.17B in profits. Earnings per share was 6.98.
Revenue5.44B
Gross Profit4.32B
Operating Income1.38B
Pretax Income1.55B
Net Income4.17B
EBITDA1.72B
Earnings Per Share (EPS)6.98
Cash Flow
In the last 12 months, operating cash flow was 542.30M and capital expenditures -252.40M, giving a free cash flow of 289.90M billion.
Operating Cash Flow542.30M
Free Cash Flow289.90M
Free Cash Flow per Share0.49
Dividends & Yields
Edwards Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change-14.63%
50-Day Moving Average71.32
200-Day Moving Average70.83
Relative Strength Index (RSI)63.15
Average Volume (3m)5.02M
Important Dates
Edwards Lifesciences upcoming earnings date is Jul 24, 2025, TBA Not Confirmed.
Last Earnings DateApr 23, 2025
Next Earnings DateJul 24, 2025
Ex-Dividend Date―
Financial Position
Edwards Lifesciences as a current ratio of 4.18, with Debt / Equity ratio of 7.00%
Current Ratio4.18
Quick Ratio3.45
Debt to Market Cap0.01
Net Debt to EBITDA-1.36
Interest Coverage Ratio69.63
Taxes
In the past 12 months, Edwards Lifesciences has paid 152.10M in taxes.
Income Tax152.10M
Effective Tax Rate0.10
Enterprise Valuation
Edwards Lifesciences EV to EBITDA ratio is 24.32, with an EV/FCF ratio of 144.54.
EV to Sales7.70
EV to EBITDA24.32
EV to Free Cash Flow144.54
EV to Operating Cash Flow77.27
Balance Sheet
Edwards Lifesciences has $3.98B in cash and marketable securities with $129.30M in debt, giving a net cash position of -$3.28B billion.
Cash & Marketable Securities$3.98B
Total Debt$129.30M
Net Cash-$3.28B
Net Cash Per Share-$5.59
Tangible Book Value Per Share$11.89
Margins
Gross margin is 78.39%, with operating margin of 25.35%, and net profit margin of 76.75%.
Gross Margin78.39%
Operating Margin25.35%
Pretax Margin28.46%
Net Profit Margin76.75%
EBITDA Margin31.68%
EBIT Margin28.82%
Analyst Forecast
The average price target for Edwards Lifesciences is $79.07, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$79.07
Price Target Upside5.24% Upside
Analyst ConsensusModerate Buy
Analyst Count18
Revenue Growth Forecast-9.84%
EPS Growth Forecast6.19%